- Home
- NMM vs NRIX Comparison
NMM vs NRIX Comparison
Compare NMM & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NMM | NRIX |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.7B |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NMM | NRIX |
|---|---|---|
| Price | $55.01 | $18.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $27.46 |
| AVG Volume (30 Days) | 96.8K | ★ 1.8M |
| Earning Date | 02-12-2026 | 01-27-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.91 | N/A |
| Revenue | ★ $1,311,114,000.00 | $83,687,000.00 |
| Revenue This Year | N/A | $59.40 |
| Revenue Next Year | $15.22 | N/A |
| P/E Ratio | $5.97 | ★ N/A |
| Revenue Growth | N/A | ★ 48.32 |
| 52 Week Low | $28.37 | $8.18 |
| 52 Week High | $56.44 | $22.50 |
Technical Indicators
Market Signals| Indicator | NMM | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 65.67 | 52.37 |
| Support Level | $50.93 | $16.98 |
| Resistance Level | $52.65 | $19.54 |
| Average True Range (ATR) | 1.19 | 0.85 |
| MACD | 0.23 | -0.37 |
| Stochastic Oscillator | 96.94 | 40.98 |
Price Performance
Historical ComparisonAbout NMM Navios Maritime Partners LP
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.